---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-045227"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T05:21:11.210900+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports FY2024 net loss $79.3M; cash $227M; VMT-α-NET enrollment reaches 30 patients

## Summary
- Net loss of $79.3M ($1.23 loss per share) vs $46.5M in FY2023; R&D spend doubled to $41.6M.
- Goodwill impairment of $24.1M due to low market cap; cash and investments $227M, funding expected into late 2026.
- VMT-α-NET Phase 1/2a enrolled 30 patients in Cohort 2 as of Feb 2025; no DLTs, one confirmed response.
- IND cleared for PSV359 (FAP-α targeting); first patient dosing expected mid-2025.
- In Feb 2025, sold 3.38M shares under ATM at ~$3.02 for gross proceeds of $10.2M.

## SEC filing metadata
- accession: 0000950170-25-045227
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025045227/0000950170-25-045227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025045227/catx-20250326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-045227
- JSON: https://secwatch.observer/filing/0000950170-25-045227.json
- Plain text: https://secwatch.observer/filing/0000950170-25-045227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.